Ajou and Chong Kun Dang Expand Their Eye-Care Portfolios
Ajou Pharmaceutical launched two ophthalmic products, while Chong Kun Dang added Korean rights to develop and commercialize an investigational retinal therapy.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Two Korean pharmaceutical companies expanded their eye-care portfolios through different routes. Ajou Pharmaceutical introduced two eye drops in September 2026, while Chong Kun Dang moved beyond product sales by adding an investigational drug candidate in August.
Ajou Pharmaceutical's additions address pupil dilation and glaucoma treatment. Chong Kun Dang's licensed candidate, KIO-301, is being developed for retinitis pigmentosa and is designed as a molecular photoswitch that acts regardless of the underlying genetic mutation.
What each company added
Ajou Pharmaceutical launched preservative-free, single-use Myo-A Eye Drops 0.125%, an atropine formulation authorized for diagnostic and therapeutic pupil dilation in children and adolescents aged 4 to 15. The company also launched single-use Aigan-P Eye Drops 0.15%, a brimonidine tartrate formulation.
Chong Kun Dang obtained Korean development and commercialization rights to KIO-301 from the U.S. company Kiora Pharmaceuticals. The candidate is designed to restore light-sensing ability in retinal ganglion cells after photoreceptor degeneration.
Limits and patient context
These portfolio additions are at different stages: Ajou Pharmaceutical's products were launched, whereas Chong Kun Dang's KIO-301 remains an investigational candidate. A licensed development right does not mean that the candidate is already available as routine treatment.
The reports do not quantify effectiveness, side effects, or recovery considerations for these products and candidates. Because individual variation can affect treatment decisions, patients and caregivers should consult a qualified ophthalmologist about suitability, risks, and available alternatives.
Questions for a consultation
For a child needing diagnostic or therapeutic pupil dilation, ask whether the authorized age range and the reported dosing schedule for Myo-A match the planned use. Ajou Pharmaceutical's stated regimen is one drop three times at five-minute intervals, once daily.
For glaucoma or retinitis pigmentosa, consult an ophthalmologist about currently appropriate care and clarify whether a product has been launched or remains under clinical development. Also ask what side effects require attention and whether follow-up or recovery planning applies to the recommended care.
Frequently asked questions
What eye products did Ajou Pharmaceutical launch?
Ajou Pharmaceutical launched Myo-A Eye Drops 0.125%, a single-use atropine formulation, and Aigan-P Eye Drops 0.15%, a single-use brimonidine tartrate formulation. Myo-A is authorized for diagnostic and therapeutic pupil dilation in patients aged 4 to 15.
Can patients receive KIO-301 now?
KIO-301 is described as an investigational candidate for retinitis pigmentosa, and Chong Kun Dang obtained its Korean development and commercialization rights. The Medical Observer report does not identify it as a treatment currently available for routine use.
How is Myo-A Eye Drops 0.125% used?
Ajou Pharmaceutical's stated regimen is one drop at a time, repeated three times at five-minute intervals, once daily. Patients and caregivers should consult an ophthalmologist before use because individual circumstances may affect the instructions.
Questions to take to an ophthalmologist
- Is this eye drop authorized for the patient's age and intended use?
- How should the stated dosing schedule be followed?
- What side effects should the patient or caregiver watch for?
- Is the treatment currently available or still in clinical development?
- How might individual variation affect follow-up and recovery planning?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
